Founded in 1983, Emcure Pharmaceuticals manufactures and globally markets a wide variety of pharmaceutical products. It has filed its draft red herring prospectus (DRHP) with the Securities Exchange Board of India (SEBI) to raise funds through an IPO (initial public offering). The company is aiming to raise ₹4,000 crore through this IPO.

The Pune-based company is the 12th largest pharmaceutical company in India. As per the CRISIL report FY21, Emcure Pharmaceutical Limited is a leader…

Pune-based Emcure Pharmaceuticals, one of India’s biggest unlisted pharma companies, filed its draft red herring prospectus (DRHP) with the market regulator Sebi on Thursday to raise money through an initial public offer.

The issue estimated to be around Rs 4,500 crore would comprise fresh shares of up to Rs 1,100 crore and an offer for sale by promoters and an existing investor of up to 18.17 million shares.

Read more at…

India’s first mRNA-based Covid-19 vaccine, from Gennova Biopharma, a subsidiary of Pune-based Emcure Pharmaceuticals, is in its final stages. Soumya Swaminathan, chief scientist at the World Health Organization (WHO), visited Gennova’s vaccine manufacturing facility at Hinjewadi in Pune on Monday. The company is awaiting regulatory approvals for its mRNA vaccine for Covid-19.…

The Central Drugs Standard Control Organisation (CDSCO), India's National Regulatory Authority, has approved Gennova Biopharmaceuticals Limited's work on the country's first mRNA-based COVID-19 vaccine for its clinical data of the phase-1 study.

"Vaccine Subject Expert Committee (SEC) reviewed the interim phase-1 data and found that HGCO19 was safe, tolerable, and immunogenic in the participants of the study. The Director General (I), CDSCO, approved the proposal submitted for the phase…

Clinical trials of the two Indian vaccine candidates—the mRNA jab from Gennova and the Receptor Binding Protein (RBD) vaccine by Biological E—are expected to speed up after the government agreed to supply doses of Covishield vaccines to these companies for a comparator study, people aware of the development said.

Both companies had been stuck with their vaccine development as they were unable to get doses from Serum Institute of India’s Covishield and Bharat Biotech’s Covaxin to…

Gennova Biopharmaceuticals’ Covid-19 jab HGCO19, based on the mRNA technology platform, will be a lyophilized vaccine or one that is based on freeze-drying. This should help store the vaccine at much higher temperatures than the stringent sub-zero temperatures required to maintain a stable cold chain for other mRNA vaccines globally.

The lyophilized vaccine will come in a powder form and it will be mixed with diluents before administration.…

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today that its development partner in India, Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials. This vaccine uses HDT Bio’s proprietary LIONTM RNA-delivery technology.…

HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today that its development partner in India, Gennova Biopharmaceuticals, successfully completed a Phase 1 trial of its COVID-19 RNA vaccine candidate HGCO19 and Indian regulatory authorities have approved the start of pivotal Phase 2/3 trials. This vaccine uses HDT Bio’s proprietary LIONTM RNA-delivery technology.…

Pune-based Gennova Biopharmaceuticals, a subsidiary of Emcure Pharma, is set to soon start phase-2 and 3 trials of India’s first mRNA based vaccine for Covid-19. “They have got regulatory approvals and the last-stage trials are expected to start soon. The company will soon start enrolment for the trials,” said a senior government official.

The study will be conducted at 10-15 sites in phase-2 and 22-27 sites in phase-3. To assess the immunogenicity of the mRNA vaccine, Gennova will…

A Tis Hazari court on Friday summoned managing director of real estate major Emaar MGF Shravan Gupta as an accused after taking cognisance of the Income Tax department's complaint against him for allegedly not furnishing details of his foreign bank accounts. Additional Chief Metropolitan Magistrate Devendra Kumar Sharma has summoned Gupta on March 24. Gupta's name, along with others, has allegedly cropped up in the black money case. The Income Tax Department, in its complaint against Gupta,…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India's first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation's first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…

For the first time, since the massive vaccination drive began, India administered more than one crore vaccine doses in a single day against Covid-19. This is the highest-ever vaccination achieved in a single day since the start of the vaccination drive in January.

In another significant achievement, India's Covid-19 vaccination coverage has crossed the 62 crore landmark and presently stands at 62,17,06,882, as per the provisional report of the Health Ministry.…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India's first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation's first mRNA-based Covid-19 vaccine.

It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot.…

The Gennova Biopharmaceuticals Ltd. is a Pune-based biotechnology company that has developed the vaccine. The interim clinical data of the Phase I trial of the vaccine was submitted for review to the Central Drugs Standard Control Organisation (CDSCO).

Dr. Sanjay Singh, CEO of Gennova Biopharmaceuticals Ltd said, “After establishing the safety of our mRNA-based COVID-19 vaccine candidate HGCO19 in Phase I clinical trial, Gennova’s focus is to start Phase II/III pivotal clinical trial.…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India’s first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation’s first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…

CBI digs deep into Emaar MGF, grills MD Shravan Gupta
The CBI on Wednesday questioned EMAAR MGF's managing director Shravan Gupta on the ongoing probe into the alleged disproportionate assets case of Kadapa MP Jaganmohan Reddy, son of late chief minister YS Rajasekhar Reddy.
https://www.moneycontrol.com/news/business/cnbc-tv18-comments/-1412763.html

The ED has again started clamping down on those involved in the AgustaWestland VVIP helicopter scam. In this episode, the ED on Wednesday raided businessman Shravan Gupta and seven places related to him. Gupta, a former director of the real-state company Emaar MGF, tightened his grip on Shravan Gupta and searched seven locations in Delhi and Gurugram in connection with the Rs 3600-crore AgustaWestland VVIP helicopter. The ED suspects that Gupta's wire Associated with money laundering,…

Former Emaar MGF Land Limited Managing Director Shravan Gupta has laundered the money generated from the Rs 3,600 crore AgustaWestland VVIP chopper deal case into bank accounts of his four shell companies located in several tax havens, sources in the Enforcement Directorate said.

​Gupta, against whom a non-bailable warrant was issued by Delhi’s Rouse Avenue Court in August, informed the court that he would not be able to travel to India to join the probe as he has “diabetes, high…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India's first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation's first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…

The Drug Controller General of India has approved the Phase 2 and 3 clinical trials of India’s first Covid-19 mRNA vaccine.

Pune-based pharma major Gennova Biopharmaceuticals Ltd is developing the nation’s first mRNA-based Covid-19 vaccine. It is among a few pharmaceutical firms worldwide, including Moderna Inc and Pfizer Inc, to use mRNA technology in its coronavirus shot. These vaccines do not use a live virus to generate an immune response but prompt the human body to make a…